GlassScriptPhysician profile
Stephen Schutzman
NPI 1407121601
$16,787.03
in general payments reported to CMS, 2019-2025
26 companies · $3,758 in 2025
The $3,758 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $3,175 · 2021: $928 · 2022: $860 · 2023: $917 · 2024: $6,662 · 2025: $3,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,149 · Travel and Lodging: $5,172 · Education: $16.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,148.81 |
| Travel and Lodging | $5,171.76 |
| Education | $16.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,142.12 | 2020-2025 | Perclose Proglide, Esprit, Jeti All In One Non-Sterile Kit |
| Medtronic, INC. | $2,710.12 | 2024 | Onyx Frontier, Symplicity G3, Ffrangio |
| Medtronic Vascular, INC. | $1,986.22 | 2019-2020 | |
| Abiomed | $1,225.57 | 2024-2025 | Impella |
| Edwards Lifesciences Corporation | $1,100.80 | 2020 | |
| Inari Medical, INC. | $766.14 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $764.17 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $667.93 | 2019-2023 | Xarelto |
| Pfizer INC. | $397.63 | 2022-2025 | |
| Amgen INC. | $371.10 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $298.67 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $282.25 | 2019-2025 | Avvigo Guidance System, Watchman Access System |
| Penumbra, INC. | $198.28 | 2020-2022 | |
| Shockwave Medical, INC | $146.61 | 2021 | |
| Cardiovascular Systems INC. | $140.97 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $140.70 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $109.73 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $96.44 | 2021-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $55.14 | 2021-2025 | Farxiga |
| Amarin Pharma, INC. | $38.41 | 2021 | |
| Acist Medical Systems, INC. | $33.28 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.41 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $27.73 | 2022-2023 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $20.81 | 2022 | |
| Cardiva Medical, INC. | $20.42 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Kiniksa Pharmaceuticals, LTD. | $14.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Schutzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.